Our Pipeline

FDL has a robust pipeline of CFTR “correctors,” “potentiators,” and “2nd generation modulators” as well as backup compounds for each of these approaches.  FDL169 has been in multiple Phase I clinical trials in both healthy volunteers and patients with CF.  FDL176 is also in clinical development.  We continue to optimize our “second generation correctors”.


Lead Identification
Lead Validation
Lead Optimization


Pre-clinical Development
Phase 1
Phase 2
  • FDL169: F508del-CFTR Corrector 80%
  • FDL169 Back-up 38%
  • FDL176: CFTR Potentiator 70%
  • FDL176 Back-up 30%
  • Second Generation Modulators 50%

Have an Idea?

We’d love to hear it!

Submit an Idea